Pharmaceutical Product Monograph: Ceftizoxime Sodium (500 mg, 1 g)
In the pharmaceutical industry, Ceftizoxime is a parenteral, semi-synthetic Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer, I view this molecule as the “Metabolically Stable Specialist”—it is technically unique because it is not metabolized by the liver and is excreted nearly 100% unchanged in the urine. This provides a very predictable pharmacokinetic profile compared to other cephalosporins.
At your WHO-GMP facility in Mumbai, Ceftizoxime is a specialized SKU often used for Pelvic and Abdominal infections. It is technically more resistant to certain beta-lactamase enzymes than Ceftriaxone, making it a powerful tool for specific resistant strains.
Therapeutic Profile: Primary Indications
Ceftizoxime is indicated for a broad range of infections, with a particular clinical strength in anaerobic and Gram-negative coverage.
| Indication | Clinical Context | Technical Rationale |
| Pelvic Inflammatory Disease (PID) | Gynecology | Gold Standard: Reaches extremely high concentrations in the female reproductive tract; covers N. gonorrhoeae. |
| Intra-abdominal Infections | Peritonitis | Effective against Bacteroides fragilis and other gut-dwelling anaerobes. |
| Bacterial Septicemia | Bloodstream Infection | Used as an empirical “heavy hitter” for systemic Gram-negative sepsis. |
| Urinary Tract Infections | Complicated UTI | Because it is excreted unchanged in the urine, it achieves massive bactericidal levels in the kidneys and bladder. |
| Meningitis | CNS Infection | Crosses the blood-brain barrier effectively when the meninges are inflamed. |
Mechanism: Cell Wall Transpeptidase Inhibition
Ceftizoxime works by sabotaging the structural grid of the bacterial cell wall:
High Affinity PBP Binding: The drug binds to Penicillin-Binding Proteins (PBPs) located on the inner bacterial cell membrane.
Peptidoglycan Synthesis Block: It inhibits the final transpeptidation (cross-linking) step of peptidoglycan synthesis.
Osmotic Lysis: Without a stable wall, the bacteria cannot withstand its own internal pressure and undergoes osmotic lysis (the cell bursts).
The Pharmacist’s “Technical Warning”
The “Liver-Safe” Advantage: As a pharmacist, I must highlight that because Ceftizoxime is not metabolized by the liver, it is an excellent choice for patients with Hepatic Impairment (liver failure).
Renal Dosing: Conversely, because it is 100% renal-cleared, the dose must be strictly reduced in patients with a $GFR < 50 \text{ mL/min}$ to prevent drug accumulation and neurotoxicity.
Probenecid Interaction: Taking Probenecid will technically slow down the excretion of Ceftizoxime, keeping drug levels in the blood higher for a longer period.
Chemical Compatibility: Do not mix Ceftizoxime and Aminoglycosides (like Amikacin) in the same IV bag; they can physically precipitate and neutralize each other.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilization” USP: On your digital marketplace, highlight your Vacuum-Dried / Lyophilized Powder. Ceftizoxime is sensitive to heat and moisture; your WHO-GMP lyophilization process ensures a stable 36-month shelf life even in Zone IVb tropical regions.
The “PID Protocol” Advantage: For international B2B tenders, market your 1 g vial as the “OB-GYN Preferred Choice.” It has a lower rate of side effects in gynecological patients compared to some older penicillins.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftizoxime 500 mg and 1 g vials to support your registration in international B2B tenders for women’s health and critical care.